Objective To evaluate the risk for major malformations following first-trimester exposure to vaginal azoles.
Introduction
The prevalence of vulvovaginal candidiasis (VVC), a common disorder that accounts for 33% of vaginitis in people, 1 is higher among women in their reproductive years and especially among pregnant women. 2, 3 The current gold standard of VVC treatment includes azole antifungal agents, which are used to treat systemic and topical fungal infections. In accordance with the guidelines of the Centers for Disease Control and Prevention (CDC), treatment during pregnancy is given only to symptomatic women and preferably in the form of topical formulations 1 due to several studies that have reported an association between first-trimester exposure to oral azoles and birth defects. [4] [5] [6] Adverse pregnancy outcomes after high-dose exposure to topical azoles during pregnancy were demonstrated in animal studies, [7] [8] [9] [10] one of which found a specific association with axial skeletal malformation. 11 Few epidemiological studies have examined the association between major congenital malformations and first-trimester exposure to vaginal azoles, in particular clotrimazole and miconazole. All of these studies, most of which found no association with major malformations, 8, [12] [13] [14] were casecontrol studies and, as such, are subjected to recall bias. In contrast, a case-control study conducted in 2008 4 found an association between azole exposure and hypoplastic left heart syndrome [adjusted odds ratio (aOR) 2.3, 95% CI 1.04-5.06] based on seven exposures among the people, three of which were to miconazole.
Given the high prevalence of VVC during pregnancy and the inconclusive evidence regarding the teratogenicity of vaginal azoles, we conducted a population-based retrospective cohort study to assess a potential association between first-trimester exposure to certain vaginal azoles and major congenital malformations.
Methods

Study population
We conducted a population-based retrospective cohort study that included all pregnancies of women from the age of 15-49 years who were registered with 'Clalit Health Services' health maintenance organisation (HMO) in southern Israel and who had a singleton birth or a pregnancy termination due to suspected fetal malformation. The study was conducted at the largest hospital in southern Israel, Soroka Medical Center (SMC), between 1 January 1999 and 31 December 2009. Approximately 70% of Israeli women of childbearing age residing in the southern district of Israel are insured by the Clalit HMO, and the vast majority of pregnancies (about 98%) are handled by SMC. 15 Excluded from the study were fetuses/terminated fetuses with chromosomal aberrations and women exposed to folic acid antagonists/other drugs that lowered folic acid levels. 16 
Databases
The cohort was created by linking four databases, one from the Clalit HMO and three from SMC, encoded by each individual's personal identification number (assigned at birth to citizens by Israel's Ministry of the Interior and used for the duration of one's life). To link each newborn/ terminated fetus with its mother, we used the unique identification number given to each hospitalisation at SMC.
The following SMC databases were used in this study: The deliveries database: provided by the Division of Obstetrics and Gynecology, which included clinical and demographic information and delivery results. SMC paediatric hospitalisation database: including data regarding major congenital malformations among newborns diagnosed until the age of 1 year and demographic data. SMC pregnancy termination database: provided data for major congenital malformations among terminated fetuses, it included all terminations done prior to 20 weeks' gestation for a fetal medical reason. All diagnoses were assigned by board-certificated neonatologists and obstetricians; primary coding was reviewed by a trained medical secretary and coded according to the International Classification of Diseases-9 (ICD-9). Data for drugs dispensed during pregnancy were provided by the Clalit HMO medication database, which included the Anatomic Therapeutic Chemical (ATC) Classification codes of the different drugs (commercial and generic names), dose schedule, and dose dispensed in defined daily dose (DDD, the assumed average maintenance dose per day).
The study was approved by the local institutional ethics committee in accordance with the principles of the Declaration of Helsinki. In accordance with Ministry of Health regulations, the institutional ethics committee did not require written informed consent because the data were obtained anonymously from medical records, with no direct participation or involvement of participants and public. As all four databases are derived from the same health organisation, all the people with births and pregnancy terminations were identified in the other two databases.
Study definitions
The first trimester was defined as the first day of the last menstrual period prior to the pregnancy and the following 90 days. The two exposure groups comprised women who were dispensed with (1) miconazole vaginal tablets (ATC5 N02BE53) or (2) clotrimazole vaginal tables (ATC5 N02BE53) during the first trimester of pregnancy. The unexposed groups comprised pregnancies that were not exposed to either drug from the azoles family (e.g. vaginal, systemic or topical formulation).
The risk of major congenital malformations was assessed for live births, stillbirths, and pregnancy terminations due to fetal medical reasons. We used the definition of major and minor congenital malformations developed by the Metropolitan Atlanta Congenital Defects Program of the CDC. [17] [18] [19] For subclass analyses of major malformations, the following specific defects were examined: anencephaly (ICD-9 code 740); spina bifida (741); other anomalies of the nervous system (742); anomalies of the eye (743); anomalies of the ear, face, and neck (744); bulbus cordis anomalies and anomalies of cardiac septal closure (745); other anomalies of the heart (746); other anomalies of the circulatory system (747); anomalies of the respiratory 
Statistical analysis
The statistical analysis was performed using SPPS software, version 21. Characteristics of the different exposure groups were compared with the unexposed group using Chi-square and Fisher's exact test for categorical variables and Student's t test for continuous variables. Given the cohort nature of the study, we decided to use negative binomial regression models to determine whether first-trimester exposure to vaginal azoles was independently associated with increased risk of major congenital malformations. The regression models were adjusted for maternal age, parity, ethnic group (Jewish versus Bedouin Muslim), smoking, pre-gestational diabetes mellitus, and year of birth or pregnancy termination. Adjusted relative risk (aRR) and 95% confidence intervals (CI) were computed. To overcome potential selection bias and to ensure similarity between the exposure groups in all covariates observed, 20 a secondary analysis for selected malformations using propensity score matching was performed. A total of 1967 pregnancies exposed to clotrimazole were compared with 7868 unexposed pregnancies, and 311 pregnancies exposed to miconazole were compared with 1863 unexposed pregnancies. The matching was performed such that the propensity for exposure to the drugs for every exposed pregnancy was as close as 0.1 SD from the propensity of the matched unexposed pregnancies. The relative risk and a 95% CI for total major malformations and for specific malformations according to organ systems were calculated.
Results
During the study period, there were 100 520 singleton births and 1095 pregnancy terminations due to fetal medical reasons at SMC to women registered with the Clalit HMO which fulfilled the inclusion criteria. A total of 5834 (5.75%) newborns/terminated fetuses were exposed to at least one of the drugs from the azoles family (oral/vaginal formulations) during the first trimester of pregnancy. Among the exposed to any azoles, 1993 mothers were exposed to clotrimazole vaginal tablets and 313 to miconazole vaginal tablets. The use of azoles, particularly miconazole and clotrimazole, remained stable during the study period ( Figure S1 ). A comparison of maternal characteristics between the two exposed groups and the unexposed group demonstrated a lower proportion of exposure to miconazole among Jewish women compared with BedouinMuslim women, but a higher exposure to clotrimazole ( Table 1 ). The proportions of diabetic women and nulliparity were higher among those exposed to clotrimazole. The adjusted risks for major and specific malformations following first-trimester exposure to clotrimazole or miconazole are summarised in Tables 2 and 3 , respectively. Among exposed pregnancies, 162 pregnancies resulted in fetal malformations: 54 in the cardiovascular system, 21 in Table 1 . Comparison of maternal characteristics and risk factors for congenital malformations among pregnancies exposed to miconazole or clotrimazole versus unexposed pregnancies the central nervous system, 41 in the musculoskeletal system, 19 in the genitourinary system, 10 in the gastrointestinal system, and 4 people of cleft lip/palate. Among the 1095 pregnancy terminations, 59 and 105 pregnancies were diagnosed by prenatal imaging with cardiac and central nervous system malformations, respectively, and 944 pregnancies were diagnosed with other major malformations.
No associations were detected between first-trimester exposure to clotrimazole and total major malformations (6.7% among exposed women compared with 6.0% in the unexposed group; aRR 1.13, 95% CI 0.93-1.13) or for specific malformations according to organ systems (Table 2) . On the other hand, the results showed a marginally significant association between exposure to vaginal miconazole and major malformations (8.9% among exposed women compared to 6.0% in the unexposed group; aRR 1.46, 95% CI 0.99-2.15; Table 3 ). An increased risk for specific malformations was found for several subgroups. The rate of musculoskeletal malformations among the miconazole exposure group was 3.2% compared with 1.5% in the unexposed group (aRR 2.10, 95% CI 1.12-3.95). This specific group of malformations is an amalgamation of three different subgroups (ICD 754, ICD 755, and ICD 756), each of which was analysed separately to determine its contribution to the observed association (Table 4) . Among the women exposed to miconazole, only one group was found to be statistically significant, exhibiting an association with other congenital musculoskeletal anomalies (ICD 756) at a rate of 1.9% compared with 0.6% in the unexposed group (aRR 3.33, 95% CI 1.48-7.51; n = 6). The subgroup of other congenital musculoskeletal malformations (ICD 756) comprises nine different subdiagnoses, of which two are due to pure genetic aetiologies (chondrodystrophies and congenital osteodystrophies) as well as three specific syndromes (Klippel-Feil syndrome, Prune belly syndrome and EhlersDanlos syndrome). The association remained significant (aOR 2.90, 95% CI 1.20-7.05) after the exclusion of these genetic aetiologies. After the exclusion of pure genetic diagnoses, five exposed people remained, of which four were born with anomalies of the face and skull bone (756.0) and one with anomalies of the diaphragm (756.6). To further examine these findings, a secondary analysis using propensity score matching for the associations mentioned above was performed. A total of 311 pregnancies that were exposed to vaginal miconazole during the first trimester were matched by propensity for exposure to miconazole with 8163 nonexposed pregnancies. No association was found between first-trimester exposure to miconazole and major malformations (aRR 1.23, 95% CI 0.78-1.85), musculoskeletal malformations (aRR 1.62, 95% CI 0.76-3.13), and other congenital musculoskeletal anomalies (ICD 756) (aRR 2.25, 95% CI 0.81-3.13). Lastly, no dose-response effect was found between exposure to vaginal antifungals as a group and major malformations (Table S1 ). When assessing that effect between exposure to miconazole vaginal tablet and other musculoskeletal malformations, no dose response was demonstrated as well.
Discussion
Main findings
The use of azoles during pregnancy is widespread due to the high prevalence of VVC. Vaginal azoles, defined as a first-line VVC treatment, are readily available in many countries as over-the-counter medications despite the lack of up-to-date information regarding their safety during pregnancy. This population-based retrospective cohort study did not demonstrate a significant association between first-trimester use of vaginal azoles and major or specific congenital malformations. We found a marginally significant association between exposure to vaginal miconazole and major malformations and a significant association between exposure to vaginal miconazole and musculoskeletal malformations using multivariate negative binomial regression models. Pharmacoepidemiological research during pregnancy is mainly observational due to ethical issues and therefore often creates groups that are not comparable in terms of background variables, which may bias the estimated effect. 21 Therefore, a propensity score matching was performed by comparing exposed with unexposed pregnancies according to the propensity to be treated with miconazole. Although this analysis did not detect an association with major malformations, a nonsignificant association was found between exposure to vaginal miconazole and musculoskeletal malformations. However, this nonsignificant association may be due to low power, as the sample size in this analysis was smaller. In the presence of previous animal studies and human case studies that showed an association between azoles and musculoskeletal malformations, 11 further study is needed to resolve this issue.
A total of 111 pregnant women were previously diagnosed with congenital heart defects. This diagnosis was previously found to be associated with cardiac malformations in the fetus. 22 We reanalysed the data after excluding those pregnancies and got similar results (total major malformation: exposed to clotrimazole RR 1.08, 95% CI 0.89-1.32, exposed to miconazole RR 1.34, 95% CI 0.89-2.02).
Topical drugs are known to be absorbed to a lesser extent than systemic drugs. Moreover, the absorption rates for vaginally administered drugs can vary widely from one , pre-gestational diabetes, smoking, nulliparity, year of delivery/pregnancy termination. **aRR was not calculated due to n < 3 of cases among the exposed group.
drug to another. 23 In a study that evaluated systemic miconazole absorption after its administration, 1-4% of the drug was absorbed systemically regardless of the initial dose given. 24 Drug passage to the intrauterine environment was possible due to the systemic presence of the absorbed drugs for 72 h. In addition, trans-cervical absorption, a potentially important route of intrauterine exposure, has never been examined. We believe that this study strengthens the results of previous studies and confirms the safety of using vaginal azoles in first trimester of pregnancy. 1 In a recently published study that assessed the risk of birth defects after first-trimester exposure to fluconazole, an association was demonstrated with cleft lip and palate. 6 Another recently published study found that oral fluconazole was associated with Tetralogy of Fallot, a specific cardiac malformation. 5 In our study, due to the low number of people among the miconazole-exposed group, we were underpowered to rule out a definite association between miconazole and this specific cardiac malformation.
The rate of major congenital malformations demonstrated in our study was higher than previous reports. 25 This finding can be attributed to the inclusion of not only deliveries but also pregnancy terminations. Furthermore, malformations were documented by board-certified neonatologists and up to 1 year of age. A comparison of Bedouin with Jewish children documented a higher rate of malformations in the former, 26 ,27 a finding that may be due to the higher rate of consanguinity among Bedouins.
Strengths and limitations
Our study is the first cohort to examine the risk for major congenital malformations in pregnancies exposed to vaginal azoles exclusively during the first trimester. The study included a large number of pregnancies, and the multivariate models were adjusted for known risk factors for fetal malformations. Furthermore, a secondary analysis using propensity score matching was performed, therefore reducing the potential for residual bias.
Our cohort also included pregnancies that ended with pregnancy terminations due to suspected fetal malformations, therefore reducing the bias towards the null hypothesis. 28 The study includes data from 70% of the parturient population in the southern district of Israel, all of whom are insured by Clalit Health Services. Because previous studies found no differences between women insured by Clalit Health Services and women insured by other maintenance organisations in southern Israel, 29 our results could be generalised to the entire population.
Although the multivariate models were adjusted for maternal diabetes before pregnancy, data regarding obesity and excessive maternal gain weight were missing in our data and therefore were not adjusted for in the multivariate models. An additional potential limitation of our study is the availability of clotrimazole as an over-the-counter drug in Israel since 2004, raising the possibility that based on prescription data alone, some exposed pregnancies might have been misclassified as unexposed. To assess whether this source of error affected our results, we performed a subanalysis that included only half of the study period (1999) (2000) (2001) (2002) (2003) , when clotrimazole was still defined as a prescription-only drug, which yielded similar results.
Lastly, our study assumed that all dispensed drugs were taken by the women, when in fact we lack data on adherence to the medication regimens. Previous studies have found high concordance rates between computerised pharmacy data and medication use in general [30] [31] [32] and even more so among pregnant women. 33 In addition, given that VVC is a symptomatic disease, it seems reasonable to assume that women who decided to purchase the medication most likely used it.
Interpretation
Our findings are consistent with the results of three previous case-control studies 8, 12, 14 that assessed the associations between vaginal clotrimazole and miconazole, and major congenital malformations. In contrast to our study, these studies did not include data regarding pregnancy terminations, nor did they assess the risk for specific systemgrouped malformations. In contrast to a case-control study that found an association between exposure to azoles as a group (no distinction as to specific drugs was made) and hypoplastic left heart syndrome, 4 our study found no association with cardiovascular malformations. Therefore, our study does not include an analysis of specific cardiovascular malformations. Further studies are needed to examine the association between these drugs and specific cardiovascular anomalies.
Conclusion
We did not find a significant association between first-trimester exposure to clotrimazole or miconazole vaginal tablets, and total major malformations or specific malformations according to organ systems. Given their widespread use during pregnancy and their availability as an over-the-counter medication in many countries, we believe the results of the current study are of important clinical significance.
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The risk of total major malformations following first-trimester exposure to vaginal antifungals according to levels of defined daily dose.&
